Axys Pharmaceuticals Advances Ulcerative
Selected Abstract
Axys Pharmaceuticals Advances Ulcerative Colitis Program Based On Encouraging Phase II Results.
Business Editors and Health/Medical Writers SOUTH SAN FRANCISCO, CalifBW HealthWireJan. 10, 2001 Axys Pharmaceuticals, Inc. (Nasdaq:AXPH) announced today that it will advance its ulcerative colitis (UC) program based on encouraging Phase II results, as demonstrated in patient response and the ... January 10, 2001; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Axys Pharmaceuticals Advances Ulcerative Colitis Program Based On Encouraging Phase II Results.
|
